| Objective:Sodium-glucose cotransporter-2(SGLT2)inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure.The activity of dapagliflozin is not related to glucose,and the effectiveness and safety of SGLT2 inhibitors in individuals with chronic heart failure(CHF)remain unclear.Therefore,using Meta—analysis to evaluate the effect of dapagliflozin in Patients with Chronic Heart Failure.Methods:We systematically retrieved Pub Med,Cochrane Library,Embase,NCKI,VIP,Wanfang Data,and Clinical Trials.gov records to identify eligible trials.The primary endpoints were cardiovascular death/hospitalization for heart failure(CV death/HHF),cardiovascular death,and hospitalization for heart failure.Secondary endpoints included hypoglycemia,volume depletion,urinary tract infection,left ventricular ejection fraction(LVEF),and NT-pro BNP.After evaluating the quality of the research literature,available data were extracted,and data analyses were performed using the Review Manager5.3 provided by Cochrane.Results:Nine randomized controlled clinical trials were included.Dapagliflozin was reported to signifificantly decrease CV death/HHF(relative risk(RR): 0.75;95% confifidence interval(CI): 0.68–0.84),CV death(RR:0.80;95%CI:0.68–0.93),and HHF(RR:0.72;95%CI: 0.63–0.83).There was no effect on hypoglycemia(RR:0.69;95%CI:0.34–1.40),volume depletion(RR: 1.17;95% CI: 0.97–1.41),urinary tract infection(RR: 0.82;95% CI:0.43–1.57),LVEF(WMD: 0.53;95% CI:-4.04–5.09),or NT-pro BNP(SMD:-0.66;95% CI:-1.42–0.10).Conclusions:The risk of CV death/HHF,CV death,and HHF was lower among patients receiving dapagliflozin than patients receiving placebo.The incidence of hypoglycemia,volume depletion and urinary tract infection could not be increased by dapagliflozin.The left ventricular ejection fraction and NT-Pro BNP were not affected by dapagliflozin. |
PDF Full Text Request